1. Home /
    2. Altai Protocol Library /
  2. New Reference: Pembrolizumab for relapsed/refractory Hodgkin lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Reference: Pembrolizumab for relapsed/refractory Hodgkin lymphoma

New Reference: Pembrolizumab for relapsed/refractory Hodgkin lymphoma
Study:
  • Randomized, open-label phase III trial (KEYNOTE-204)
  • Relapsed or refractory classical Hodgkin lymphoma who had received or were ineligible for auto-SCT
  • Pembrolizumab (n=151) vs. brentuximab vedotin (n=153), both for 35 cycles or until disease progression
Efficacy:
  • ORR: 65.6% vs. 54.2% (NS)
  • CR: 25% vs. 24% (NS)
  • Median PFS: 13.2 vs. 8.3 mos (HR: 0.65 [0.48-0.88])
  • Median DoR: 20.7 vs. 13.8 mos
  • OS analysis not performed at this interim analysis
Safety:
  • Grade >=3 AEs: neutropenia (2% vs. 7%), febrile neutropenia (0% vs. 1%), pneumonitis (4% vs. 1%), pneumonia (2% vs. 1%)

Lancet Oncol 2021; 22: 512–24

Kuruvilla J, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

https://doi.org/10.1016/S1470-2045(21)00005-X

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More